Q1 2020 Sartorius AG Earnings Call Transcript
Good afternoon, and good morning, everybody, depending on where you are. Welcome to our conference call on our Q1 results 2020 for both the Sartorius Group as well as for Sartorius Stedim Biotech. As always, I'm sharing this together with Rainer Lehmann, our CFO. And the structure of our presentation is, again, that we first walk you through the results for Sartorius AG or the Sartorius Group, I should say. And then after, we share the information for Sartorius Stedim Biotech, and then we have time for Q&A.
So I would like to start off with highlighting the most important results from Q1. So first of all, we have been able to achieve double-digit growth for all most relevant KPIs: order intake, sales revenue and underlying EBITDA. The impact from the pandemic crisis has been neutral on a group level, but, for sure, was quite different for the 2 divisions, and you'll see that in a minute. For Bioprocess Solutions, we have achieved quite dynamic top line growth, particular strong order intake, because this has been
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
